Amneal Pharmaceuticals (AMRX) said Thursday that the Veterans Administration, UnitedHealthcare (UNH), and CVS Health (CVS) have added Parkinson's disease treatment Crexont to their national prescription drug formularies.
The company said the additional coverage increases the total US insurance coverage of Crexont to more than 50% of covered patients from about 30% at the end of 2024. Amneal added it had previously set a target of over 50% coverage by the end of 2025.
Price: 8.10, Change: -0.07, Percent Change: -0.86
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.